TABLE 1.
Characteristics of the Non-Small Cell Lung Cancer Patients Cohorts
| Characteristics | Bevacizumab/Erlotinib (n =35a) | ECOG 3503 (n = 82) | VU Control (n = 61) |
|---|---|---|---|
| Sex (%) | |||
| Male | 14 (40) | 37 (45.1) | 42 (68.9) |
| Female | 21 (60) | 45 (54.9) | 19 (31.1) |
| Age (yr) | |||
| Median | 59 | 70 | 65 |
| Range | 36–72 | 41–93 | 40–84 |
| Stage | |||
| IIIB | N/Ab | 7 (8.5) | 28 (45.9) |
| VI | N/Ab | 59 (72.0) | 33 (54.1) |
| Recurrent | 16 (19.5) | ||
| RECIST (%) | |||
| Partial response | 8 | N/A | N/A |
| Stable disease | 21 | N/A | N/A |
| Progressive disease | 6 | N/A | N/A |
| Survival (mo) | |||
| Overall (95% CI) | 15.25 (7.75-inf) | 7.69 (5.39–10.05) | 14.63 (10.3–27.27) |
| Progression-free (95% CI) | 4 (2.25–12.5) | 3.38 (2.07–3.91) | |
a
The total number of patients with available clinical data for survival analysis.
b
The total number of patients in the bevacizumab/erlotinib trial was 40 (seven IIIb, 32 IV, one unknown).
CI, confidence interval; N/A, not applicable; RECIST, Response Evaluation Criteria in Solid Tumors.